FDA Acceptance of Auransa’s IND Application for AU409 for Treatment of Patients with Hepatocellular Carcinoma

Auransa, Inc. announced that the US FDA has accepted its Investigational New Drug (IND) application for AU409, a novel, orally active agent showing anticancer activity in preclinical studies of HCC.